Nivolumab to pembrolizumab switch induced a durable melanoma response: A case report.

ABSTRACT:

Rationale

While checkpoint inhibitors have revolutionized the treatment of melanoma, it is not known whether switching from one monoclonal antibody drug to another one would be justified in the case of a treatment failure. Herein, we report a case illustrating a durable response to pembrolizumab after a failure with nivolumab.

Patient concerns

A 76-year-old white male noticed an enlarging papular lesion on his neck.

Diagnosis

Malignant melanoma.

Interventions

The patient underwent surgery in December 2013 and was found to have a B-Rapidly Accelerated Fibrosarcoma (BRAF) V600E mutated melanoma. Treatment with BRAF and MAPK/Erk kinase (MEK) inhibitors along with radiation was initiated. After 1 year, the disease progressed, and the treatment was switched to the c

SUBMITTER: Lepir T 

PROVIDER: S-EPMC6336603 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature